Davis ID - Search Results

1

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.

Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, Francis RJ, Zhang AY, Scott AM, Lee ST, Azad AA, McJannett MM, Stockler MR, Williams SG, Davis ID, Hofman MS; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Buteau JP, et al. Among authors: davis id. Lancet Oncol. 2022 Nov;23(11):1389-1397. doi: 10.1016/S1470-2045(22)00605-2. Epub 2022 Oct 16. Lancet Oncol. 2022. PMID: 36261050 Clinical Trial.

2

Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma.

Ramdave S, Thomas GW, Berlangieri SU, Bolton DM, Davis I, Danguy HT, Macgregor D, Scott AM. Ramdave S, et al. J Urol. 2001 Sep;166(3):825-30. J Urol. 2001. PMID: 11490227

3

The use of dendritic cells in cancer therapy.

Jefford M, Maraskovsky E, Cebon J, Davis ID. Jefford M, et al. Among authors: davis id. Lancet Oncol. 2001 Jun;2(6):343-53. doi: 10.1016/s1470-2045(00)00389-2. Lancet Oncol. 2001. PMID: 11905751 Review.

4

18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy.

Johns Putra L, Lawrentschuk N, Ballok Z, Hannah A, Poon A, Tauro A, Davis ID, Hicks RJ, Bolton DM, Scott AM. Johns Putra L, et al. Among authors: davis id. Urology. 2004 Dec;64(6):1202-7. doi: 10.1016/j.urology.2004.07.024. Urology. 2004. PMID: 15596197

5

Impact of 2-deoxy-2[F-18]fluoro-D-glucose Positron Emission Tomography on the management of patients with advanced melanoma.

Harris MT, Berlangieri SU, Cebon JS, Davis ID, Scott AM. Harris MT, et al. Among authors: davis id. Mol Imaging Biol. 2005 Jul-Aug;7(4):304-8. doi: 10.1007/s11307-005-0002-7. Mol Imaging Biol. 2005. PMID: 16041590

6

Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship.

Lawrentschuk N, Davis ID, Bolton DM, Scott AM. Lawrentschuk N, et al. Among authors: davis id. BJU Int. 2006 May;97(5):916-22. doi: 10.1111/j.1464-410X.2006.06125.x. BJU Int. 2006. PMID: 16643471 Review. No abstract available.

7

Positron emission tomography and molecular imaging of the prostate: an update.

Lawrentschuk N, Davis ID, Bolton DM, Scott AM. Lawrentschuk N, et al. Among authors: davis id. BJU Int. 2006 May;97(5):923-31. doi: 10.1111/j.1464-410X.2006.06040.x. BJU Int. 2006. PMID: 16643472 Review. No abstract available.

8

Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: current practice.

Lawrentschuk N, Davis ID, Bolton DM, Scott AM. Lawrentschuk N, et al. Among authors: davis id. Int J Urol. 2007 Feb;14(2):89-95. doi: 10.1111/j.1442-2042.2006.01659.x. Int J Urol. 2007. PMID: 17302562 Review.

9

Immunotherapy of advanced or metastatic melanoma.

Cebon J, Gedye C, John T, Davis ID. Cebon J, et al. Among authors: davis id. Clin Adv Hematol Oncol. 2007 Dec;5(12):994-1006. Clin Adv Hematol Oncol. 2007. PMID: 18277962 Review.

10

Predicting clinical outcome through molecular profiling in stage III melanoma.

John T, Black MA, Toro TT, Leader D, Gedye CA, Davis ID, Guilford PJ, Cebon JS. John T, et al. Among authors: davis id. Clin Cancer Res. 2008 Aug 15;14(16):5173-80. doi: 10.1158/1078-0432.CCR-07-4170. Clin Cancer Res. 2008. PMID: 18698035

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

308 results

Search Page